Search PubMed⌕ Search

Biomedical subjects

W Böhning

Publications and source records attributed to W Böhning.

18 recordsLinked to original sources
PubMed2000

Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison.

The main objective of the study was to compare the long-term safety and tolerability of fenoterol hydrobromide delivered using a metered-dose inhaler formulated with the alternative propellant, hydrofluoroalkane 134a (HFA-MDI), with delivery using the currently available chlorofluorocarbon MDI (CFC-MDI; Berotec 100). A further objective was to compare the efficacy of fenoterol HFA-MDI with fenoterol CFC-MDI, using the pulmonary function parameters of forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC) and peak expiratory flow (PEF). Following a 2-week run-in phase, a 12-week, double-blind parallel group comparison was undertaken in 290 patients randomized on a 2:1 basis to two puffs of 100 microg fenoterol four times a day (HFA-MDI=197 patients; CFC-MDI=93 patients). A total of 236 patients in this multi-centre study completed the trial as planned. The overall incidence of adverse events (AEs) was similar in both groups (29.9% of HFA-MDI patients and 28% of CFC-MDI patients). Reports of respiratory disorder AEs were also comparable (21.8% HFA-MDI; 22.6% CFCMDI). End of study laboratory tests, ECG, pulse, blood pressure and physical examination showed no significant differences from pre-study baselines in either group and both treatments appeared to be well tolerated. Pre-dose FEV1 measurements taken at the three clinic visits were constant and increase in FEV1 at 5 and 30 min post-dose demonstrated equivalent efficacy for the two formulations. No difference between the two groups was observed in PEF or in the use of rescue medication. We conclude from these findings that the long-term safety and efficacy profile of fenoterol HFA-MDI is comparable to that of the fenoterol CFC-MDI.

Adolescent↗
PubMed1995

Amoxicillin/clavulanic acid vs cefetamet pivoxil in the treatment of acute exacerbation of chronic bronchitis (AECB) in adults.

In this open comparative and prospective study 180 adults of either sex were randomised to treatment with either amoxicillin/clavulanic acid (AMC) 500/125mg tid or cefetamet pivoxil (CAT) 500mg bid for 7 days. Demographic data and assessable findings were similar in both groups. Clinical outcomes of 169 assessable patients showed high efficacy of both drugs: 92% with AMC and 96% with CAT. Bacteriological response rates were equivalent in 141 evaluable cases: 84% vs. 89%, respectively. Baseline susceptibility testing (DIN) revealed a notable number of Haemophilus species either intermediately susceptible or resistant to AMC. Gastrointestinal disorders predominated among the adverse events with diarrhea occurring nearly twice as often in the AMC group. CAT is an effective and safe alternative option in the treatment of AECB in adults. The advantage of CAT is its enhanced activity against gram-negative bacteria. It is well tolerated.

Acute Disease↗
PubMed1990

[Anaphylactic shock after sucking on a throat lozenge].

A few minutes after sucking a lozenge for a sore throat a 68-year-old man developed an anaphylactic shock. At a heart rate of 110/min there was no palpable blood pressure. A red confluent exanthem, predominantly of the trunk, was noted. After brief intensive-care treatment the patient was completely well again and diagnostic tests for allergy were performed. The prick test for the 14 individual ingredients of the throat lozenge produced massive reddening and urticaria on the test arm with carbowax, a polyethylene glycol which serves as a vehicle in the remedy and does not have to be listed. Later there were an urge to cough and urticaria all over the trunk. There was no systemic reaction. Neither specific IgE antibodies nor any complement-consuming reaction could be demonstrated. Thus the precipitating mechanism remains unexplained.

4-Aminobenzoic Acid↗
PubMed1990

[Intranasal salmon calcitonin for the prophylaxis of bone mineral loss in steroid-treated chronic obstructive lung diseases ].

In the present controlled study the effect of calcitonin nasal spray (CAS 47931-85-1; Lachs-Calcitonin Nasal spray Sandoz) on the bone mineral content was investigated in 36 patients in need of corticosteroid therapy suffering from chronic, obstructive lung diseases. The treatment consisted of 200 IU intranasal daily and lasted for one year. In the control group there was a statistically significant decline of bone mineral content of 5% or 4.3% concerning the lumbar vertebrae L1-L4 and the femur, whereas in the treated group there was only a statistically not significant decrease of 0.9% and 0.8%, respectively. These findings show that calcitonin nasal spray in a dose of 200 IU daily is quite useful for the prophylaxis of steroid-induced osteoporosis.

Administration, Intranasal↗
PubMed1990

[Does COPD affect bone mineral content?].

In a retrospective study, 85 COPD patients not treated with steroids, and 78 who received steroid therapy, were compared with a control group of normal subjects (n = 126) matched for age and sex. The determination of the bone mineral content (BMC) was carried out with the aid of two-photon absorption measurement performed in the region of the lumbar spine L2-4 and of the neck of the femur. With respect to the distribution of the bone mineral content as a function of sex and pulmonary function reduction, the following results were obtained: 1. There are significant differences between men and women. The BMC is generally lower in women. 2. Significant differences are to be found between the normal subject group and the steroid-free group on the one hand, and the steroid-treated group on the other. The group receiving steroid treatment has appreciably lower BMC values. 3. There are statistically significant correlations between the severity of airway obstruction and the decrease in BMC both in steroid-treated and steroid-free patients.

Aged↗
PubMed1990

[Long-term therapy with almitrine dimesilate has no effect on pulmonary hemodynamics at rest and during stress].

A 6-month double-blind study was conducted in 26 patients suffering from a severe obstructive disturbance of ventilation and respiratory insufficiency to find out the behaviour of blood gases and pulmonary haemodynamics under Almitrin treatment compared with placebo. The acute administration of 75 mg Almitrin resulted in a significant increase of PaO2 by 11.7 mmHg, as well as of PAPR by 4.4 mmHg. Statistical significance was seen only for the systolic pressure of the a. pulmonalis. After subsequent 6-month treatment with 3 x 25 mg Almitrin, a significantly higher PaO2 is seen at T6 than in the control group. Another additional administration of 75 mg Almitrin results in a further increase of PaO2 by 7.7 mmHg. At T6 the behaviour of pulmonary haemodynamics is identical in both groups A and P.

Almitrine↗
PubMed1976

[Elevated creatine kinase activity in serum following oral application of a beta2-mimetic broncholytic drug (NAB 365) (author's transl)].

In 25 patients with chronic bronchitis it was shown by a study of 9 months' duration (3 months before treatment, 6 months under treatment) that after peroral application of 4-amino-alpha-[(tert.-butylamino)methyl]-3,5-dichlorobenzyl alcohol hydrochloride (clenbuterol, NAB 365) elevations of the activity of creatine kinase occur without other recognizable signs and symptoms. The isoenzyme of creatine kinase were differentiated by immunological means and proved to be of the MM-type in additional 9 patients. The significance of the elevations of creatine kinase activity in serum even after peroral intake of drugs has been discussed.

Adult↗